Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: Long-term follow-up of a randomized, placebo-controlled trial

Haematologica

Volumn 93, Issue 10, 2008, Pages 1588-1590

  Voskaridou, Ersi ^a   Christoulas, Dimitrios ^b   Konstantinidou, Marialena ^c   Tsiftsakis, Evangelos ^b   Alexakos, Panagiotis ^c   Terpos, Evangelos ^b  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^c Novartis Hellas 12th Km National Road Athens Lamia   (Greece)

Author keywords

Bisphosphonates; Bone mineral density; Osteoporosis; Thalassemia; Zoledronic acid

Indexed keywords

ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

BETA THALASSEMIA; BONE DENSITY; BONE NECROSIS; BONE PAIN; BONE REMODELING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; JAW OSTEONECROSIS; LETTER; LONG TERM CARE; OSTEOPOROSIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; THALASSEMIA MAJOR; TREATMENT DURATION; VERTEBRA FRACTURE;

ADULT; BIOLOGICAL MARKERS; BONE DENSITY; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; MALE; OSTEOPOROSIS; PAIN; THALASSEMIA; TIME FACTORS;

EID: 54349085318     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12849     Document Type: Letter

References (12)

1. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with β thalassaemia. Br J Haematol 2004;127:127-39.
2. Voskaridou E, Kyrtsonis MC, Terpos E, Skordili M, Theodoropoulos I, Bergele A, et al. Bone resorption is increased in young adults with thalassaemia major. Br J Haematol 2001;112:36-41.
3. Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C, Meo A, et al. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int 2002;13:644-9.
4. Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, et al. Pamidronate is an effective treatment for osteoporosis in patients with β-thalassaemia. Br J Haematol 2003;123:730-7.
5. Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Stoupa E, Spyropoulou E, Kiamouris C, et al. Zoledronic acid for the treatment of osteoporosis in patients with β-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica 2006;91:1193-202.
6. Otrock ZK, Azar ST, Shamseddeen WA, Habr D, Inati A, Koussa S, et al. Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Ann Hematol 2006;85:605-9.
7. Perifanis V, Vyzantiadis T, Tziomalos K, Vakalopoulou S, Garipidou V, Athanassiou-Metaxa M, et al. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with β-thalassaemia. Ann Hematol 2007;86:23-30.
8. Rodan G, Reszka A, Golub E, Rizzoli R. Bone safety of long term bisphosphonates treatment. Curr Med Res Opin 2004;20:1291-300.
9. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years' experience with alendronate for osteoporosis in post-menopausal women. N Engl J Med 2004;350:1189-99.
10. Landman JO, Hamdy NA, Pauwels EK, Papapoulos SE. Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. J Clin Endocrinol Metab 1995;80:3465-8.
11. Gasser JA, Ingold P, Venturiere A, Shen V, Green JR. Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res 2008;23:544-51.
12. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-38.